Saying that the Risk Evaluation and Mitigation Strategies (REMS) program for clozapine may prevent access to treatment, the Food and Drug Administration (FDA) last year said the REMS is no longer necessary.
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from The Brown University Child & Adolescent Psychopharmacology Update